Vesalio Advances pVasc NET with FDA 510(k) Clearance
Dallas, Texas, August 13, 2026 Vesalio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dallas, Texas, August 13, 2026 Vesalio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...
San Diego, California, August 13, 2026 Atrium Therapeutics, Inc. announced that it has earned a $15 million milestone payment...
Fruita, Colorado, August 12, 2026 Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared...
